CY1109914T1 - Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα - Google Patents

Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα

Info

Publication number
CY1109914T1
CY1109914T1 CY20091100702T CY091100702T CY1109914T1 CY 1109914 T1 CY1109914 T1 CY 1109914T1 CY 20091100702 T CY20091100702 T CY 20091100702T CY 091100702 T CY091100702 T CY 091100702T CY 1109914 T1 CY1109914 T1 CY 1109914T1
Authority
CY
Cyprus
Prior art keywords
soft
bioavailability
improved stability
panolosetron
include hydrochloride
Prior art date
Application number
CY20091100702T
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgo Calderari
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109914(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare S.A. filed Critical Helsinn Healthcare S.A.
Publication of CY1109914T1 publication Critical patent/CY1109914T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχονται στερεές στοματικές δοσολογικές μορφές της υδροχλωρικής παλονοσετρόνης, μέθοδοι χρησιμοποίησης των δοσολογικών μορφών για θεραπεία της έμεσης, και μέθοδοι παρασκευής των δοσολογικών μορφών. Οι δοσολογικές μορφές έχουν βελτιώσει την σταθερότητα και βιοδιαθεσιμότητα, και είναι κατά προτίμηση σε κάψουλες υγρού περιεχόμενου.
CY20091100702T 2006-10-24 2009-07-03 Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα CY1109914T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
EP07819163A EP1940366B9 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (1)

Publication Number Publication Date
CY1109914T1 true CY1109914T1 (el) 2014-09-10

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100702T CY1109914T1 (el) 2006-10-24 2009-07-03 Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα

Country Status (36)

Country Link
US (2) US20080152704A1 (el)
EP (1) EP1940366B9 (el)
JP (1) JP5144527B2 (el)
KR (1) KR101441459B1 (el)
CN (1) CN101573106B (el)
AR (1) AR063362A1 (el)
AT (1) ATE427742T1 (el)
AU (1) AU2007308378B2 (el)
BR (1) BRPI0718497B1 (el)
CA (1) CA2666512C (el)
CL (1) CL2007003055A1 (el)
CO (1) CO6160289A2 (el)
CR (1) CR10728A (el)
CY (1) CY1109914T1 (el)
DE (1) DE602007000856D1 (el)
DK (1) DK1940366T3 (el)
EA (1) EA016455B1 (el)
ES (1) ES2325339T3 (el)
GT (1) GT200900096A (el)
HK (1) HK1117769A1 (el)
HN (1) HN2009000785A (el)
HR (1) HRP20090341T1 (el)
IL (1) IL198225A (el)
ME (1) ME01949B (el)
MX (1) MX2009004461A (el)
NO (1) NO342353B1 (el)
NZ (1) NZ576237A (el)
PL (1) PL1940366T3 (el)
PT (1) PT1940366E (el)
RS (1) RS50842B (el)
SI (1) SI1940366T1 (el)
SV (1) SV2009003238A (el)
TW (1) TWI367212B (el)
UA (1) UA97653C2 (el)
WO (1) WO2008049552A1 (el)
ZA (1) ZA200902773B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410093A (zh) * 2006-01-27 2009-04-15 欧兰德股份有限公司 包含弱碱性药物和有机酸的药物递送系统
NZ570039A (en) * 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
CN102781939A (zh) * 2009-11-13 2012-11-14 赫尔辛医疗股份公司 帕洛诺司琼代谢物
JP5890780B2 (ja) 2009-11-18 2016-03-22 ヘルシン ヘルスケア ソシエテ アノニム 中枢を介する悪心および嘔吐を治療するための組成物および方法
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
DK2744497T3 (en) 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
CN103446072A (zh) * 2012-06-02 2013-12-18 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
RU2015144543A (ru) * 2013-03-19 2017-04-27 Галеникум Хелс С.Л. Фармацевтические композиции, содержащие активное вещество
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
BR112016014880A2 (pt) * 2013-12-23 2017-08-08 Samyang Biopharmaceuticals Composição farmacêutica incluindo palonosetron
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
IL96486A (en) * 1989-11-28 1995-03-30 Syntex Inc Preparation tricyclic compounds and pharmaceutical preparations containing them
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
CR10728A (es) 2009-07-23
CL2007003055A1 (es) 2008-03-24
CO6160289A2 (es) 2010-05-20
GT200900096A (es) 2011-08-29
PT1940366E (pt) 2009-06-17
HK1117769A1 (en) 2009-01-23
DE602007000856D1 (de) 2009-05-20
CA2666512C (en) 2014-05-27
NO20091945L (no) 2009-05-25
HRP20090341T1 (en) 2009-07-31
JP5144527B2 (ja) 2013-02-13
UA97653C2 (ru) 2012-03-12
IL198225A (en) 2013-03-24
IL198225A0 (en) 2009-12-24
EP1940366A1 (en) 2008-07-09
US20170035748A1 (en) 2017-02-09
SV2009003238A (es) 2009-11-09
ME01949B (me) 2010-08-31
EA016455B1 (ru) 2012-05-30
NZ576237A (en) 2011-12-22
TWI367212B (en) 2012-07-01
BRPI0718497B1 (pt) 2024-02-06
ATE427742T1 (de) 2009-04-15
AU2007308378B2 (en) 2013-02-21
CA2666512A1 (en) 2008-05-02
ES2325339T3 (es) 2009-09-01
EP1940366B1 (en) 2009-04-08
AR063362A1 (es) 2009-01-21
AU2007308378A1 (en) 2008-05-02
EP1940366B9 (en) 2009-12-02
TW200827355A (en) 2008-07-01
SI1940366T1 (sl) 2009-08-31
RS50842B (sr) 2010-08-31
BRPI0718497A2 (pt) 2014-07-08
WO2008049552A1 (en) 2008-05-02
DK1940366T3 (da) 2009-06-29
MX2009004461A (es) 2009-09-16
CN101573106B (zh) 2013-07-24
JP2009507933A (ja) 2009-02-26
CN101573106A (zh) 2009-11-04
KR20090073234A (ko) 2009-07-02
HN2009000785A (es) 2011-10-14
KR101441459B1 (ko) 2014-09-18
ZA200902773B (en) 2010-03-31
NO342353B1 (no) 2018-05-07
PL1940366T3 (pl) 2009-09-30
US20080152704A1 (en) 2008-06-26
EA200970396A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
CY1109914T1 (el) Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
NO2018028I2 (no) Kombinasjonen alogliptin og pioglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
DE602005009811D1 (de) Tetrahydrocarbazole und derivate
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
DK1673349T3 (da) Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
NO345140B1 (no) Anvendelse av humane IL-1beta bindende antistoffer og farmasøytiske sammensetninger inneholdende slike, for fremstilling av et medikament for behandling av juvenil reumatoid artritt
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
ATE389398T1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
CY1111656T1 (el) Παραγωγα αλφα-αμινοαμιδιου χρησιμα εις την θεραπευτικη αγωγη εθιστικων παθησεων
IS8220A (is) Bensímídasólafleiður, blöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
DK1718340T3 (da) Nye effektorkonjugater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
CY1108711T1 (el) Συνθεσεις βενζοθειαζολιου και η χρηση αυτων
DK2083007T3 (da) Tiotropiumsalte, fremgangsmåder til deres fremstilling og lægemiddelformuleringer indeholdende disse
DK1791872T3 (da) Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse
DK1944298T3 (da) Quinazolinderivat og lægemiddel